Growth plate-targeted IGF1 to treat Turner Syndrome
生长板靶向 IGF1 治疗特纳综合征
基本信息
- 批准号:10819340
- 负责人:
- 金额:$ 27.46万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-22 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AccelerationAddressAdultAdverse effectsAffectAffinityAgeAntibodiesAvidityBindingBiodistributionBiological AssayBiological Response Modifier TherapyBiological SciencesBirthBone GrowthBone LengtheningChimeric ProteinsChondrocytesClinicalClinical TrialsComplementCongenital chromosomal diseaseDoseDrug KineticsEpiphysial cartilageExtracellular Matrix ProteinsFDA approvedFUS-1 ProteinFailureFemaleFluorochromeFoundationsFrequenciesFutureGenerationsGenesGoalsGrowthHalf-LifeHeightHormonesHumanHyperglycemiaHypoglycemiaIGF1 geneIn VitroInjectionsInsulin ResistanceInsulin-Like Growth Factor IInsulin-Like Growth-Factor-Binding ProteinsInsulin-Like-Growth Factor I ReceptorIntracranial HypertensionLabelLeadLiverLymphoid TissueMeasurementModificationMusNasopharynxNormal RangeOsteogenesisPatientsPharmaceutical PreparationsPhasePhenotypePre-Clinical ModelProductionProliferatingPropertyProto-Oncogene Proteins c-aktRare DiseasesRecombinant Growth HormoneRecombinant IGF-ISafetySerumSignal TransductionSmall Business Innovation Research GrantSomatotropinStructureTestingToxic effectTurner&aposs SyndromeUnited States National Institutes of HealthVariantX Chromosomearmbonecandidate identificationclinical developmentdesigndrug candidateefficacy evaluationefficacy studyefficacy testingestablished cell lineexperimental studygrowth hormone deficiencyhealthy volunteerhigh riskimprovedin vivoinnovationlead candidatelead optimizationlong bonemanufacturabilitymatrilin 3mouse modelnext generationpharmacologicpre-clinicalpreclinical studyprogramsprototypepublic health relevancer-hGH-Msafety studyskeletalstandard of caretargeted treatment
项目摘要
Turner syndrome (TS) is a rare disorder that occurs at a rate of 1 in 2500 live female births and is caused by
partial or complete monosomy of the X chromosome. Among the most common phenotypes in TS patients is
short stature, defined as at least 2 standard deviations below mean height for age, which is commonly treated
with daily injections of recombinant human growth hormone (GH) as the standard of care. While GH statistically
increases adult height, TS patients generally fail to reach their mid-parental height projection or even achieve
adult heights within the normal range. Additionally, TS patients are at particularly high risk for adverse effects
associated with prolonged GH treatment that include hyperglycemia, intracranial hypertension, growth of the
nasopharyngeal lymphoid tissues, insulin resistance, and acromegalic changes. Cavalry Biosciences’ goal is to
address the unmet clinical need in safety and efficacy by developing a targeted therapeutic consisting of IGF1
(GH effector that drives bone growth) and an anti-matrilin-3 (MATN3) antibody-based target arm that drives
localization to growth plates of long bones. In preclinical studies, prototypes of such a Growth Plate IGF1 (GP-
IGF1) biotherapeutics, selectively localized to and increased the size of growth plates in mouse models of GH
deficiency. The objective of our Phase 1 proposal is to optimize this prototype molecule into a lead that has PK-
PD-efficacy and manufacturability properties that are favorable for clinical advancement. To accomplish this
objective, we will pursue two specific aims. In the first aim, we will design and express next-generation GP-IGF1
fusions proteins with modifications that (i) improve MATN3 binding to optimize GP targeting, (ii) alter IGF1’s
affinity for IGF1R and/or ability to interact with activity inhibiting IGF-binding proteins, and (iii) optimize pharma-
cokinetics (PK). The resulting molecules will be tested for their ability to bind MATN3 and activate IGF1R in vitro
and in vivo using assays that we have developed in preliminary studies. Candidate molecules will be assessed
for PK and biodistribution properties in mice. In the second aim, we will use preclinical models to evaluate the
efficacy and safety of next-gen GP-IGF1 molecules relative to recombinant GH and IGF1. Growth plate height
measurements in GH-inhibited mice will be used for initial efficacy testing of the next-gen GP-IGF1 molecules
generated through our drug optimization program. Because growth plate height is a surrogate for chondrocyte
proliferation and bone growth, these experiments will be complemented with direct measurements of chondro-
cyte proliferation and bone formation. Lead molecules will then be murinized for use in longer-term experiments
that will critically evaluate (i) the extent to which they accelerate long bone growth and (ii) the potential for adverse
effects. At the successful completion of Phase 1, we will have identified a lead compound that has been tested
in mice for PK, biodistribution, PD, efficacy, and safety. This will lay the foundation for a Phase 2 application, in
which we will conduct the IND-enabling studies that advance our lead molecule to a drug candidate suitable for
human testing.
特纳综合症(TS)是一种罕见的疾病,发病率为1/2500活产女婴,由以下原因引起:
X染色体的部分或完全单体性。TS患者中最常见的表型之一是
身材矮小,定义为低于年龄平均身高至少2个标准差,通常治疗
每天注射重组人生长激素(GH)作为标准治疗。而GH统计学
增加成人身高,TS患者通常无法达到其父母身高预测的中间值,甚至无法达到
成人身高在正常范围内。此外,TS患者的不良反应风险特别高
与长期GH治疗相关,包括高血糖症、颅内高压、
鼻咽淋巴组织、胰岛素抵抗和肢端肥大症改变。Cavalry Biosciences的目标是
通过开发由IGF 1组成的靶向治疗药物,解决安全性和有效性方面未满足的临床需求
(GH驱动骨生长的效应器)和基于抗基质蛋白-3(MATN3)抗体的靶臂,所述靶臂驱动
定位于长骨的生长板。在临床前研究中,这种生长板IGF1(GP-1)的原型被证实是一种新的生长板。
IGF1)生物治疗剂,选择性定位于生长板,并增加生长板的大小,在小鼠模型的生长激素
缺陷我们的第一阶段提案的目标是将这种原型分子优化为具有PK-
有利于临床进步的PD有效性和可制造性特性。为了实现这一
我们将追求两个具体目标。在第一个目标中,我们将设计和表达下一代GP-IGF1
具有修饰的融合蛋白,所述修饰(i)改善MATN3结合以优化GP靶向,(ii)改变IGF 1的
对IGF1 R的亲和力和/或与抑制IGF结合蛋白活性的相互作用的能力,以及(iii)优化药物
共动力学(PK)。将测试所得分子在体外结合MATN 3和激活IGF1R的能力
和体内实验,这些实验都是我们在初步研究中开发的。将评估候选分子
用于小鼠中的PK和生物分布特性。在第二个目标中,我们将使用临床前模型来评估
下一代GP-IGF 1分子相对于重组GH和IGF 1的有效性和安全性。生长板高度
GH抑制小鼠的测量结果将用于下一代GP-IGF1分子的初始功效测试
通过我们的药物优化计划产生。因为生长板高度是软骨细胞的替代品
增殖和骨生长,这些实验将补充软骨的直接测量,
细胞增殖和骨形成。铅分子随后将被制成鼠模型用于长期实验
这将严格评估(i)它们加速长骨生长的程度和(ii)不良反应的可能性。
方面的影响.在第一阶段成功完成后,我们将确定一种经过测试的先导化合物
在小鼠中进行PK、生物分布、PD、功效和安全性。这将为第二阶段的应用奠定基础,
我们将进行IND使能研究,将我们的先导分子推进到适合于
人体测试
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Timothy Richard Stowe其他文献
Timothy Richard Stowe的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 27.46万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 27.46万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 27.46万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 27.46万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 27.46万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 27.46万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 27.46万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 27.46万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 27.46万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 27.46万 - 项目类别:
Research Grant